ORAGENICS WKN: A2JBK2 ISIN: US6840233026 Kürzel: UAVP Forum: Aktien Thema: Hauptdiskussion

Warum 😄

⚠️ Aus Ende Vorbei ⚠️

War's das hier?

bis auf ein paar Spitzen nach oben, geht die Aktie seit Anfang 21 stetig bergab

ach so , jetzt verstehe ich wie Du das meintest, ja kann man so sehen, wenn hier keine News kommen geht es wohl weiter berg ab

du meinst unter

Bald sind wir über 30 Cent froh

Also nie

Ich verkauf erst bei 30 €

10 000 stck EK 0,35 sollte man raus gehen mit kleinem Verlust oder warten bis 0,10 oder was ich nicht mehr glaube 1 Euro, 30 kommen hier niemals

Denke auch da es ein flopp Investment war

Also nie 🙈😁

Verkauft wird erst bei 30 €

Denke auch das dieses Investment ein Flop ist. Leider 🥲

hier ist genauso wenig los wie mit der Aktie selber, manche träumen hier von 10...30 Euro, ja ein Euro wäre schon mal super, sieht eher nach 0,20 aus zur Zeit

Company to showcase NT-CoV2-1, a patient-friendly Covid vaccine candidate TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronavirus, today announced that Kimberly Murphy, a member of the Company’s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an intranasal vaccine candidate, and to pursue business development opportunities. The NT-CoV2-1 intranasal vaccine program approach is focused on patient-friendly administration, reducing transmission through a mucosal immune response, and to provide long-lasting protection. As a recombinant protein and adjunctive vaccine, NT-CoV2-1 is differentiated compared to live-attenuated intranasal vaccines candidates that may cause greater side effects and harder to produce. Animal models have demonstrated NT-CoV2-1 intranasal formulation induced robust immune responses, lowering the viral load below detection of the assay in the nasal passages and the lungs. Currently, an IND-enabling GLP toxicology study is ongoing. The Company expects to initiate a first-in-human Phase 1 trial in previously vaccinated healthy adults this year. Ms. Murphy joined Oragenic’s Board of Directors in 2020 and actively provides vital insight to the Company’s strategic corporate and development objectives. Formerly, she served in a variety of vaccine-related leadership roles within GlaxoSmithKline plc (GSK). While with GSK, Ms. Murphy led the global influenza vaccine and pandemic preparedness businesses and was responsible for the strategic and prelaunch planning for multiple development-stage vaccines through commercialization. Earlier in her career, she worked in commercialization roles within Merck and Novartis Vaccines and Diagnostics Inc. Ms. Murphy currently serves as a director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as a director (chairperson) of Clarus Therapeutics Holdings Inc. (NASDAQ: CRXT).